There is promising new data from the makers of ONCOS-102 that shows that the treatment can help improve the long-term survival of mesothelioma patients. ONCOS-102 was recently given Fast-Track approval by the FDA to speed up its development. ONCOS-102 is a modified adenovirus that infects cancer cells. The new mesothelioma[…]
Pleural Mesothelioma
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy (MESOIMMUNE)
Primary Outcome Measures Disease control [ Time Frame: 12 weeks ] Disease control rate at 12 weeks Secondary Outcome Measures Survival with anti-PD1/PDL1 immunotherapy [ Time Frame: 12 weeks ] Overall survival from treatment with anti-PD1/PDL1 immunotherapy Duration of treatment [ Time Frame: 12 weeks ] Duration of treatment with PD1/PDL1 immunotherapy Survival [ Time Frame: 12 weeks ] Overall survival from the start of the[…]
Researchers are Developing a Test to Determine Which Mesothelioma Patients Will Benefit From Immunotherapy
Doctors want to figure out which pleural mesothelioma patients will best benefit from certain chemotherapy drugs. Currently there are no tests to see what immunotherapy drugs might work on a specific patient. This leads to doctors trying out different treatments that have negative side effects to only find out the[…]
Genetic Testing Could Help Reduce Mesothelioma Cases and Help the Survival of Those Suffering from the Disease
Researchers believe that early genetic testing for genetic mutations can help reduce the cases of mesothelioma and can help increase the survival of those suffering from the disease. Researchers found that new mutations in the BLM gene were making people more susceptible to developing mesothelioma after being exposed to asbestos.[…]
Nivolumab Can Help Increase the Survival in Mesothelioma Patients Whose Cancer Has Relapsed
A study in the United Kingdom involving 332 patients who cannot receive surgery (unresectable) found that patients whose mesothelioma has relapsed can be treated with nivolumab safely. Nivolumab is an immunotherapy drug known as Opdivo, which is popular for treating non-small cell lung cancer. Opdivo is promising because it is[…]
Gemcitabine Used as a Maintenance Therapy Could Help Mesothelioma Patients Live Longer
Using maintenance therapy with gemcitabine alongside chemotherapy can help increase survival in patients compared to patients just receiving palliative care. Gemcitabine is an antimetabolite, which prevents cancer cells from dividing into new cancer cells. Chemotherapy is usually the first line treatment for mesothelioma, and if patients are able to receive[…]
SMART Mesothelioma Procedure Could Extend the Lives of Certain Mesothelioma Patients
Accelerated high dose radiation before surgery created a 65.9 month survival for mesothelioma patients. They were part of a clinical trial in Toronto at the Princess Margaret Cancer Center. The study is named SMART, an acronym for Surgery for Mesothelioma After Radiation Therapy. There were 96 patients who were treated[…]
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced malignant MPM.
Thoracic Chemotherapy After Surgery Could Help Pleural Mesothelioma Patients Survive Longer
Hyperthermic intrathoracic chemotherapy alongside aggressive therapy (HITHOC) could help extend pleural mesothelioma patient survival. Doctors perform this by circulating a heated high concentration chemotherapy solution in the chest cavity for one hour right after aggressive surgery is performed on a patient. They do this to kill microscopic tumor cells that[…]
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
Primary Outcome Measures Occurrence of Dose Limiting Toxicity [ Time Frame: over the first 21 days of dosing ] Incidence of Adverse and Serious Adverse Events Occurrence of General Toxicity [ Time Frame: through study completion, an average of 30 months ] Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety Evaluations[…]
Skip to content